Valiant Laboratories
Limited

September 28, 2026

To,
Listing/Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

BSE CODE – 543998

To,
Listing/Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G-Block, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: VALIANTLAB

Dear Sir/ Madam,

Sub: Proceedings of the 5th Annual General Meeting of Valiant Laboratories Limited held on Monday, September 28, 2026 at 11:30 AM (IST).

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith summary of the proceedings of the 5th Annual General Meeting of the Company held on **Monday, September 28, 2026 at 11:30 A.M. (IST)** through Video Conferencing (VC) /Other Audio Visual Means (OAVM).

This intimation is also being uploaded on the Company's website at www.valiantlabs.in

Please take note of the above on your record.

Thanking you,

Yours Faithfully,

For Valiant Laboratories Limited

AKSHAY DNYANESHWAR GANGURDE
Digitally signed by AKSHAY DNYANESHWAR GANGURDE
Date: 2026.09.28 17:34:48 +05'30'

Akshay Gangurde
Company Secretary & Compliance Officer

Encl: As above

Proceedings of the 5th Annual General Meeting of the Company held on Monday, September 28, 2026, at 11:30 A.M. (IST)

Present:

Mr. Mulesh Savla	-	Chairman of the Company & Independent Director
Mr. Santosh Vora	-	Managing Director
Mr. Paresh Shah	-	Whole Time Director & Chief Financial Officer
Mr. Shantilal Vora	-	Non – Executive Director
Mr. Sandeep Gupta	-	Non – Executive Director
Mr. Ashok Chheda	-	Independent Director
Mr. Akshay Gangurde	-	Company Secretary

In attendance:

- Mr. Raman Shah, Statutory Auditor, representing M/s. Raman S. Shah & Co.
- Mrs. Monali Bhandari, Secretarial Auditor & Scrutinizer, representing M/s. Mehta and Mehta.
- Other management representatives and consultants.

ATTENDANCE:

38 members attended the Annual General Meeting ('AGM') through Video Conferencing ('VC')/Other Audio Visual Means ('OAVM').

PROCEEDINGS:

Mr. Akshay Gangurde, Company Secretary, welcomed the members to the 5th Annual General Meeting of the Company and provided general instructions regarding participation and voting.

He informed the Members that Mrs. Sonal Vira, Independent Director of the Company, was unable to attend the Meeting due to her personal exigencies and had sought leave of absence. He further informed that Mrs. Sonal Vira, being the Chairperson of the Nomination and Remuneration Committee, had, in accordance with the Secretarial Standard on General Meetings (SS-2), authorised Mr. Shantilal Vora, a member of the Nomination and Remuneration Committee, to attend the Meeting on her behalf as the representative of the Committee.

Thereafter, **Mr. Mulesh Savla, Chairman of the Company**, extended a warm welcome to all the members. With the consent of the members present, the **Notice of the Meeting and the Auditors' Report** were taken as read. He then requested the Company Secretary to introduce the Board members.

The Board of Directors were formally introduced to the shareholders.

Members were informed that, in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, the Company had provided **remote e-voting facility** prior to the AGM, and **e-voting facility during the AGM** for all resolutions set out in the Notice. The e-voting shall remain open for **30 minutes' post conclusion of the meeting.**

COMPANY OVERVIEW:

After the brief introduction, with the permission of the Chairman, Mr. Santosh Vora, Managing Director, was requested to present the performance highlights of the Company.

Mr. Santosh Vora, Managing Director, addressed the Members and presented an overview of the Company's performance during FY 2025-26. He briefed the Members on the industry landscape and informed that the Company witnessed improved business performance during the year, supported by stabilising market conditions in the paracetamol API sector. He highlighted the successful completion of the Rights Issue, achievement of a debt-free balance sheet and commencement of commercial operations at the wholly owned subsidiary, Valiant Advanced Sciences Private Limited. He further apprised the Members of the Company's focus on backward integration, operational excellence, quality standards and safety initiatives. He also shared the progress made by Valiant Advanced Sciences Private Limited in commercialising its products and expanding its presence in specialty chemicals. He outlined the Company's key priorities for FY 2026-27, including supporting the subsidiary's growth, strengthening export opportunities, enhancing operational efficiencies and pursuing international quality and regulatory certifications. He concluded by expressing gratitude to the shareholders, employees, customers, business partners, bankers, regulators and other stakeholders for their continued support and confidence in the Company.

RESOLUTIONS TRANSACTED:

The following **items of business**, as set out in the Notice, were transacted at the Meeting:

Ordinary Business		
Item No.1	To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March	Ordinary Resolution

	31, 2026, together with the Reports of the Board of Directors and the Auditors thereon.	
Item No.2	To appoint a director in place of Mr. Sandeep Gupta (DIN: 09245060), Non-Executive Director, who retires by rotation and who being eligible, offers himself for re-appointment.	Ordinary Resolution
Special Business		
Item No.3	Ratification of remuneration to the Cost Auditors for the Financial Year 2026-27.	Ordinary Resolution
Item No.4	Approval of Material Related Party Transaction(s) with Valiant Organics Limited.	Ordinary Resolution
Item No.5	Approval of Material Related Party Transaction(s) with Aarti Pharmalabs Limited.	Ordinary Resolution
Item No.6	Approval of Material Related Party Transaction(s) between Valiant Advanced Sciences Private Limited and Valiant Organics Limited.	Ordinary Resolution
Item No.7	Approval of Material Related Party Transaction(s) between Valiant Advanced Sciences Private Limited and Aarti Pharmalabs Limited.	Ordinary Resolution
Item No.8	Approval of Material Related Party Transaction(s) between Valiant Advanced Sciences Private Limited and Alchemie Speciality Chemicals Private Limited.	Ordinary Resolution
Item No.9	Re-appointment of Mr. Santosh Vora (DIN: 07633923) as Managing Director of the Company for a period of 5 years and to fix his remuneration.	Special Resolution
Item No.10	Re-appointment of Mrs. Sonal Vira (DIN: 09505883) as an Independent Director for the second term of five consecutive years.	Special Resolution
Item No.11	Revision in remuneration of Mr. Paresh Shah (DIN: 08291953), Whole-Time Director and Chief Financial Officer.	Special Resolution
Item No.12	Continuation of Directorship of Mr. Shantilal Vora (DIN: 07633852) as a Non-Executive Non-Independent Director of the Company, upon attaining 75 years of age.	Special Resolution
Item No.13	Payment of remuneration by way of	Special Resolution

	commission to Mr. Shantilal Vora (DIN: 07633852), Non-Executive Director of the Company.	
Item No.14	Payment of remuneration by way of commission to Mr. Sandeep Gupta (DIN: 09245060), Non-Executive Director of the Company.	Special Resolution
Item No.15	Payment of remuneration by way of commission to Mr. Mulesh Savla (DIN: 07474847), Independent Director of the Company.	Special Resolution
Item No.16	Payment of remuneration by way of commission to Mrs. Sonal Vira (DIN: 09505883), Independent Director of the Company.	Special Resolution
Item No.17	Payment of remuneration by way of commission to Mr. Ashok Chheda (DIN: 10776571), Independent Director of the Company.	Special Resolution
Item No.18	Shifting of the Registered Office of the Company outside the jurisdiction of the existing Registrar of Companies (ROC) within the State of Maharashtra.	Special Resolution

SHAREHOLDER INTERACTION:

The Company Secretary invited the pre-registered speaker shareholders to express their views and queries.

The pre-registered speakers participated and shared their queries during the meeting. Mr. Santosh Vora, Managing Director responded to the queries raised and provided the necessary clarifications.

E-VOTING AND CONCLUSION:

The Company Secretary reminded members who had not voted earlier to cast their votes through the e-voting facility provided during the AGM. It was informed that M/s. Mehta and Mehta, Practicing Company Secretaries, were appointed as Scrutinizer to scrutinize the voting process.

Since all items of business had been transacted, the Chairman thanked the members for their participation and cooperation.

Valiant Laboratories
Limited

The meeting was concluded at 12:04 P.M. and e-voting remained open for a further 30 minutes.

Note: This document does not constitute the minutes of the Annual General Meeting.

For Valiant Laboratories Limited

AKSHAY DNYANESHWAR GANGURDE

Digitally signed by AKSHAY DNYANESHWAR GANGURDE
Date: 2026.09.28 17:36:31 +05'30'

Akshay Gangurde
Company Secretary & Compliance Officer
Date: September 28, 2026